8-K
AbCellera Biologics Inc. (ABCL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 7, 2025
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
| British Columbia | 001-39781 | Not Applicable | |||
|---|---|---|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | 150 W 4th Avenue<br><br>Vancouver, BC | V5Y 1G6 | |
| --- | --- | ||||
| (Address of registrant’s principal executive office) | (Zip code) |
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common shares | ABCL | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On August 7, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended August 7, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure
In connection with its earnings call on August 7, 2025, to discuss its results for the quarter ended June 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| Exhibit<br>No. | Description |
|---|---|
| 99.1 | Press Release issued by AbCellera Biologics Inc. onAugustq22025earningspressrelease.htm7, 2025. |
| 99.2 | Corporate presentation. |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 7, 2025 | ABCELLERA BIOLOGICS INC. | |
|---|---|---|
| By: | /s/ Carl L. G. Hansen | |
| Carl L. G. Hansen, Ph.D. | ||
| Chief Executive Officer and Director<br><br>(Principal Executive Officer) |
Document
NEWS RELEASE
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
8/7/2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Today we also announced that a third program, ABCL688, has advanced into IND-enabling studies. With over $750 million in available liquidity, we are well-positioned to continue to execute our strategy.”
Q2 2025 Business Summary
●Generated a net loss of $34.7 million, compared to a net loss of $36.9 million in 2024.
●Received authorization from Health Canada to initiate Phase 1 clinical trials for ABCL635 and ABCL575, bringing the cumulative total of molecules to reach the clinic to 18.
●Advanced ABCL688, an ion channel- or GPCR-targeted antibody development candidate (autoimmunity), into IND/CTA-enabling studies.
●Presented preclinical data for ABCL575 at the Society for Investigative Dermatology.
●Reached a cumulative total of 102 partner-initiated program starts with downstreams.
Recent Developments
●ABCL635 (Endocrinology/Women's Health): AbCellera has initiated dosing of participants in a Phase 1 clinical trial of ABCL635, a potential non-hormonal, long-acting treatment for moderate-to-severe VMS, commonly known as hot flashes, associated with menopause. This is a randomized, placebo-controlled, double-blind Phase 1 study in healthy men and postmenopausal women with or without VMS. Its purpose is to evaluate safety, pharmacokinetics, pharmacodynamics, as well as frequency and severity of VMS with subcutaneous doses of ABCL635. The initial safety and efficacy data from this study is expected to be presented in mid 2026.
●ABCL575 (Immunology and Inflammation): AbCellera has initiated a Phase 1 clinical trial of ABCL575, which is being developed for the treatment of moderate-to-severe atopic dermatitis. This is a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575. ABCL575 is an OX40-ligand-targeting antibody engineered to support a dosing interval of once every 6 months.
Key Business Metrics
| Cumulative Metrics | June 30, 2024 | June 30, 2025 | Change % | |
|---|---|---|---|---|
| Partner-initiated program starts with downstreams | 93 | 102 | 10 | % |
| Molecules in the clinic | 14 | 18 | 29 | % |
AbCellera started discovery on an additional five partner-initiated programs with downstreams to reach a cumulative total of 102 partner-initiated program starts with downstreams in Q2 2025 (up from 93 on June 30, 2024). AbCellera and its partners have advanced a cumulative total of 18 molecules into the clinic (up from 14 on June 30, 2024).
Discussion of Q2 2025 Financial Results
●Revenue – Total revenue was $17.1 million, compared to $7.3 million in Q2 2024.
●Research & Development (R&D) Expenses – R&D expenses were $39.2 million, compared to $40.9 million in Q2 2024. A greater proportion of R&D expenses are used on internal programs reflecting the increased emphasis on building the internal pipeline.
●Sales & Marketing (S&M) Expenses – S&M expenses were $3.0 million, compared to $3.1 million in Q2 2024.
●General & Administrative (G&A) Expenses – G&A expenses were $19.0 million, compared to $20.2 million in Q2 2024.
●Net Loss – Net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, compared to net loss of $36.9 million, or $(0.13) per share on a basic and diluted basis, in Q2 2024.
●Liquidity – $580 million of total cash, cash equivalents, and marketable securities and approximately $173 million in available non-dilutive government funding, bringing total available liquidity to approximately $753 million to execute on AbCellera's strategy.
Conference Call and Webcast
AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.
Definition of Key Business Metrics
We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops.
Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term.
Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached "open" status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding
our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Source: AbCellera Biologics Inc.
Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116
AbCellera Biologics Inc.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2024 | 2025 | 2024 | 2025 | |||||
| Revenue: | ||||||||
| Research fees | $ | 5,453 | $ | 6,639 | $ | 15,227 | $ | 10,707 |
| Licensing revenue | 370 | 10,445 | 550 | 10,613 | ||||
| Milestone payments | 1,500 | – | 1,500 | – | ||||
| Total revenue | 7,323 | 17,084 | 17,277 | 21,320 | ||||
| Operating expenses: | ||||||||
| Research and development(1) | 40,927 | 39,213 | 80,214 | 81,711 | ||||
| Sales and marketing(1) | 3,136 | 3,009 | 6,501 | 5,851 | ||||
| General and administrative(1) | 20,192 | 18,977 | 37,544 | 35,203 | ||||
| Depreciation, amortization, and impairment | 36,522 | 5,470 | 41,366 | 10,801 | ||||
| Total operating expenses | 100,777 | 66,669 | 165,625 | 133,566 | ||||
| Loss from operations | (93,454) | (49,585) | (148,348) | (112,246) | ||||
| Other (income) expense: | ||||||||
| Interest income | (9,801) | (7,592) | (20,202) | (15,643) | ||||
| Grants and incentives | (3,310) | (3,692) | (6,585) | (7,845) | ||||
| Other | (32,156) | (1,957) | (30,627) | 570 | ||||
| Total other income | (45,267) | (13,241) | (57,414) | (22,918) | ||||
| Net loss before income tax | (48,187) | (36,344) | (90,934) | (89,328) | ||||
| Income tax recovery | (11,257) | (1,617) | (13,394) | (8,980) | ||||
| Net loss | $ | (36,930) | (34,727) | $ | (77,540) | $ | (80,348) | |
| Foreign currency translation adjustment | (257) | 4,341 | (353) | 1,721 | ||||
| Comprehensive loss | $ | (37,187) | $ | (30,386) | $ | (77,893) | $ | (78,627) |
| Net loss per share | ||||||||
| Basic | $ | (0.13) | $ | (0.12) | $ | (0.26) | $ | (0.27) |
| Diluted | $ | (0.13) | $ | (0.12) | $ | (0.26) | $ | (0.27) |
| Weighted-average common shares outstanding | ||||||||
| Basic | 294,217,013 | 298,508,601 | 293,467,753 | 298,105,760 | ||||
| Diluted | 294,217,013 | 298,508,601 | 293,467,753 | 298,105,760 |
(1) Exclusive of depreciation, amortization, and impairment
AbCellera Biologics Inc.
Condensed Consolidated Balance Sheets
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)
| December 31, 2024 | June 30, 2025 | |||
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 156,325 | $ | 92,437 |
| Marketable securities | 469,289 | 460,641 | ||
| Total cash, cash equivalents, and marketable securities | 625,614 | 553,078 | ||
| Accounts and accrued receivable | 33,616 | 47,310 | ||
| Restricted cash | 25,000 | 25,000 | ||
| Other current assets | 67,140 | 116,757 | ||
| Total current assets | 751,370 | 742,145 | ||
| Long-term assets: | ||||
| Property and equipment, net | 340,429 | 424,020 | ||
| Intangible assets, net | 42,113 | 40,262 | ||
| Goodwill | 47,806 | 47,806 | ||
| Investments in equity accounted investees | 82,297 | 90,374 | ||
| Other long-term assets | 96,538 | 57,454 | ||
| Total long-term assets | 609,183 | 659,916 | ||
| Total assets | $ | 1,360,553 | $ | 1,402,061 |
| Liabilities and shareholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable and other current liabilities | $ | 55,004 | $ | 50,074 |
| Contingent consideration payable | 8,087 | – | ||
| Deferred revenue | 13,521 | 16,949 | ||
| Total current liabilities | 76,612 | 67,023 | ||
| Long-term liabilities: | ||||
| Operating lease liability | 60,743 | 137,184 | ||
| Deferred revenue | 5,700 | 11,633 | ||
| Deferred government contributions | 149,893 | 167,532 | ||
| Deferred tax liability | 10,052 | 10,053 | ||
| Other long-term liabilities | 1,469 | 1,560 | ||
| Total long-term liabilities | 227,857 | 327,962 | ||
| Total liabilities | 304,469 | 394,985 | ||
| Commitments and contingencies | ||||
| Shareholders' equity: | ||||
| Common shares: no par value, unlimited authorized shares at December 31, 2024 and June 30, 2025: 295,757,002 and 298,652,967 shares issued and outstanding at December 31, 2024 and June 30, 2025, respectively | 777,171 | 791,668 | ||
| Additional paid-in capital | 166,361 | 181,483 | ||
| Accumulated other comprehensive loss | (4,378) | (2,657) | ||
| Accumulated earnings | 116,930 | 36,582 | ||
| Total shareholders' equity | 1,056,084 | 1,007,076 | ||
| Total liabilities and shareholders' equity | $ | 1,360,553 | $ | 1,402,061 |
AbCellera Biologics Inc.
Condensed Consolidated Statement of Cash Flows
(Expressed in thousands of U.S. dollars.)
(Unaudited)
| Six months ended June 30, | ||||
|---|---|---|---|---|
| 2024 | 2025 | |||
| Cash flows from operating activities: | ||||
| Net loss | $ | (77,540) | $ | (80,348) |
| Cash flows from operating activities: | ||||
| Depreciation of property and equipment | 6,603 | 8,951 | ||
| Amortization and impairment of intangible assets | 34,763 | 1,851 | ||
| Amortization of operating lease right-of-use assets | 3,437 | 2,863 | ||
| Stock-based compensation | 35,191 | 28,993 | ||
| Fair value gain on contingent consideration | (30,920) | 737 | ||
| Other | (8,193) | (667) | ||
| Changes in operating assets and liabilities: | ||||
| Research fees and grants receivable | (34,434) | (12,524) | ||
| Income taxes receivable | (5,953) | (7,588) | ||
| Accounts payable and accrued liabilities | (130) | (7,356) | ||
| Deferred revenue | (12,782) | 9,361 | ||
| Deferred grant income | 19,757 | (1,681) | ||
| Other assets | (1,473) | 13,450 | ||
| Net cash used in operating activities | (71,674) | (43,958) | ||
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (44,250) | (24,001) | ||
| Purchase of marketable securities | (426,007) | (291,542) | ||
| Proceeds from marketable securities | 539,385 | 303,437 | ||
| Receipt of grant funding | 19,750 | 6,448 | ||
| Long-term investments and other assets | 3,950 | (13,783) | ||
| Investment in equity accounted investees | (10,820) | (4,435) | ||
| Net cash provided by (used in) investing activities | 82,008 | (23,876) | ||
| Cash flows from financing activities: | ||||
| Payment of contingent consideration and other | (368) | (9,058) | ||
| Proceeds from long-term liabilities and exercise of stock options | 5,850 | 11,653 | ||
| Net cash provided by financing activities | 5,482 | 2,595 | ||
| Effect of exchange rate changes on cash and cash equivalents | (824) | 1,351 | ||
| Increase (decrease) in cash and cash equivalents | 14,992 | (63,888) | ||
| Cash and cash equivalents and restricted cash, beginning of period | 160,610 | 183,615 | ||
| Cash and cash equivalents and restricted cash, end of period | $ | 175,602 | $ | 119,727 |
| Restricted cash included in other assets | 2,290 | 2,290 | ||
| Total cash, cash equivalents, and restricted cash shown on the balance sheet | $ | 173,312 | $ | 117,437 |
| Supplemental disclosure of non-cash investing and financing activities | ||||
| Property and equipment in accounts payable | 15,944 | 12,733 | ||
| Right-of-use assets obtained in exchange for operating lease obligation | 452 | 69,787 |
7
abcl2025q2businessupdate
CO PY RI GH T © A BC EL LE RA August 7, 2025 Q2 2025 BUSINESS UPDATE
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. 2 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e
3 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Completed transition into clinical-stage biotech and on track to complete key priorities. ABCL635 Phase 1 clinical trials initiated (June 2025) ABCL575 Phase 1 clinical trials initiated (July 2025) Completion of platform investments by the first half of the year Initiation of activities at the new clinical manufacturing facility Nominated an additional development candidate for CTA-enabling studies (ABCL688) in available liquidity to execute on our strategy ~$750M 2025 PRIORITIES
4 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Neurokinin 3 receptor (NK3R) First participants dosed in Phase 1 clinical trial of ABCL635, a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes). Target G protein-coupled receptor (GPCR) Target Type Moderate-to-severe vasomotor symptoms (VMS) associated with menopause Indication Endocrinology / women’s health Therapeutic Area INTERNAL PIPELINE & PROGRAMS The Phase 1 clinical trial of ABCL635 is a randomized, placebo-controlled, double- blind study in healthy men and post- menopausal women with or without VMS. Its purpose is to evaluate safety, pharmacokinetics, pharmacodynamics, as well as frequency and severity of VMS with subcutaneous doses of ABCL635. The initial safety and efficacy data from this study is expected to be presented in mid 2026. Status
5 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e ABCL575 has a projected dosing interval of once every 6 months. Modeled exposure based on preclinical PK data* 600 mg loading dose*** 300 mg maintenance doses Time (weeks) A BC L 57 5 co nc en tr at io n (µ g/ m L) 90% prediction interval 50% prediction interval Median Clinical efficacy threshold** The predicted human half-life is 67 days based on mouse pharmacokinetic (PK) data. ABCL575 is expected to maintain circulating concentrations above the efficacy threshold for amlitelimab (4 µg/mL) with clinically feasible, infrequent dosing. * Illustrative of projected dosing of ABCL575 based on PK modeling; parameters were estimated using allometric scaling of Tg32 PK model fits,3 70% bioavailability, and literature.4, 5 Figure is not representative of clinical data. ** Amlitelimab demonstrates clinical efficacy at doses of 0.45 mg/kg1 and ≥62.5 mg Q4W SC2 suggesting a threshold PK concentration of 4 µg/mL required for efficacy. *** A loading dose and maintenance dose regimen is simulated for ABCL575 as use of a loading dose has shown to lead in greater improvements in clinical endpoints for amlitelimab.2 1. Saghari M, et al. (2022). Clin Pharmacol Ther. 111(5):1121-1132. 2. Weidinger, S. et al. (2025). J Allergy Clin Immunol. 155(4):1264-1275. 3. Haraya K, et al. (2025). mAbs.17(1):2484443. 4. Betts A, et al. (2018). mAbs. 10(5):751-764. 5. Haraya K, et al. (2017). Drug Metab Pharmacokinet. 32(4):208-217. INTERNAL PIPELINE & PROGRAMS
6 CO PY RI GH T © A BC EL LE RA MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase I Phase 2 Phase 3 ABCL635 NK3R Endocrinology & Women’s Health ABCL575 OX40L Immunology & Inflammation ABCL688 Undisclosed GPCR / ion channel Autoimmunity Q2 2 02 5 Bu si ne ss U pd at e Advanced ABCL688, the second program from our GPCR / ion channel platform, into IND/CTA-enabling studies. * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission INTERNAL PIPELINE & PROGRAMS 20+ discovery programs in the pipeline
7 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Q2 2025 FINANCIALS UPDATE
8 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e We have the capabilities and the capital to execute on our strategy. in total available government funding*~$170M in total cash, cash equivalents, & marketable securities*~$580M in available liquidity to execute on our strategy*~$750M * As of June 30, 2025
9 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS Cumulative # of MOLECULES IN THE CLINIC Cumulative # of Note: Showing year-end figures except for most-recent quarter. Historical results are not necessarily indicative of future results. Notable Updates on Continuing portfolio growth with first AbCellera-led programs entering clinic. MOLECULES IN THE CLINIC AbCellera-led Partner-led Molecule This Update ABCL635 Phase 1 initiated ABCL575 Phase 1 initiated
10 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Operating expenses reflect R&D investments. Operating Expenses USDRevenue USD Q2 2025Q2 2024 $40.9M $39.2M -$1.7M Q2 2025Q2 2024 $3.1M $3.0M -$0.1M Q2 2025Q2 2024 $20.2M $19.0M -$1.2M RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMINLICENSING RESEARCH FEES MILESTONES $10.4M Q2 2025 $6.6M Q2 2024 $7.3M $17.1M $5.5M Research fees Licensin g Milestones
11 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Net loss of $35M; equivalent to ($0.12) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2024 Q2 2025 ($36.9M) ($34.7M) Q2 2024 Q2 2025 Post-production ❑ Move “Q” labels down ($0.13) ($0.12)
12 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e Approximately $580M in total cash, equivalents, and marketable securities. Cash Flows USD * Restricted cash (including restricted cash in other assets) INVESTING FINANCING ($36M) Other FX $461M Marketable Securities $92M Cash & Equivalents $469M Marketable Securities Jun 30, 2025 $12M Marketable Securities (net) OPERATINGDec 31, 2024 $27M* $156M Cash & Equivalents $653M ($44M) ($24M) $3M $1M $580M $27M*
13 CO PY RI GH T © A BC EL LE RA Q2 2 02 5 Bu si ne ss U pd at e THANK YOU